Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

Jing Jiao, Shunyou Wang, Rong Qiao, Igor Vivanco, Philip A. Watson, Charles L. Sawyers, and Hong Wu

Abstract

PTEN mutations are among the most frequent genetic alterations found in human prostate cancers. Our previous works suggest that although precancerous lesions were found in Pten heterozygous mice, cancer progression and metastasis only happen when both alleles of Pten were deleted. To understand the molecular mechanisms underlying the role of PTEN in prostate cancer control, we generated two pairs of isogenic, androgen receptor (AR)–positive prostate epithelial lines from intact conditional Pten knock-out mice that are either heterozygous (PTEN-P2 and -P8) or homozygous (PTEN-CaP2 and PTEN-CaP8) for Pten deletion. Further characterization of these cells showed that loss of the second allele of Pten leads to increased anchorage-independence growth in vitro and tumorigenesis in vivo without obvious structural or numerical chromosome changes based on SKY karyotyping analysis. Despite no prior exposure to hormone ablation therapy, Pten null cells are tumorigenic in both male and female severe combined immunodeficiency mice. Furthermore, knocking down Pten can convert the androgen-dependent Myc-CaP cell into androgen independence, suggesting that PTEN intrinsically controls androgen responsiveness, a critical step in the development of hormone refractory prostate cancer. Importantly, knocking down AR by shRNA in Pten null cells reverses androgen-independent growth in vitro and partially inhibited tumorigenesis in vivo, indicating that PTEN-controlled prostate tumorigenesis is AR dependent. These cell lines will serve as useful tools for understanding signaling pathways controlled by PTEN and elucidating the molecular mechanisms involved in hormone refractory prostate cancer formation. [Cancer Res 2007;67(13):6083–91]

Introduction

Prostate cancer is the second leading cause of cancer-related death among North American men (1). Despite improved early detection and initial positive response to androgen ablation therapies, almost all patients eventually develop hormone refractory prostate cancer (HRPC). The molecular mechanisms leading to the progression of HRPC are still poorly understood (2), with proposed hypotheses ranging from gain of function mutations under hormone deprivation to intrinsic properties of certain prostate cancer cells (3).

Among genetic alterations frequently found in human prostate cancers, PTEN loss of function has been strongly implicated in prostate cancer development (4, 5). The etiologic role of PTEN in prostate tumorigenesis is further supported by studying animal models with prostate-specific deletion of its murine homologue, the Pten gene (6–8). In contrast to conventional heterozygous Pten deletion (6, 9, 10), conditional deletion of both alleles of Pten significantly reduces the latency of prostate intraepithelial neoplasia (PIN) lesion development and further progression to localized adenocarcinoma followed by metastasis (6–8). Therefore, the onset and progression of prostate cancer are PTEN dosage dependent (6). Similar to the majority of human prostate cancers, Pten null murine prostate cancer initially regress in response to androgen ablation therapy, but subsequently relapse and proliferate in the absence of androgens (7). Therefore, the Pten prostate cancer model (7) provides an ideal system for studying the mechanism of HRPC (11).

To our knowledge, the most well-studied human prostate cancer cell lines such as LNCaP (12), PC3 (13), and DU145 (14) are derived from late-stage cancer samples after hormone ablation therapy and therefore, are not ideal for studying the processes involved in HRPC. To circumvent this, we attempted to establish primary cell lines from intact Pten conditional knock-out mice (7). Here, we report the establishment and characterization of two pairs of isogenic cell lines and their usage to address (a) whether prostatic epithelial cells can acquire androgen independency without androgen deprivation and (b) the relationship between loss of PTEN and androgen-independent growth.

Materials and Methods

Establishment of primary cell lines from Pten prostate cancer model. Prostate cancer tissue was dissected from a 10-month intact Pten<sup>loxp/loxp;PB-Cre<sup>4+</sup> mouse (7), minced, and digested with 0.5% type I collagenase (Invitrigen) using the same protocol as the generation of Myc-CaP line (15). After filtering through a 40-μm mesh, the fragments trapped by the mesh were plated in tissue culture dishes coated with type I collagen (BD Pharmingen). Several cell populations with distinct epithelial morphology were observed in the confluent monolayer developed from the tissue fragments. Cells with typical epithelial morphology were collected, and single cell was plated into each well of a 96-well plate. The Pten-P2 and Pten-P8 cell lines were independently established as spontaneously immortalized lines. The lines were maintained in DMEM supplemented with 10% fetal bovine serum (FBS; Omega Scientific), 25 μg/mL bovine pituitary extract, 5 μg/mL bovine insulin, and 6 ng/mL recombinant human epidermal growth factor (Sigma-Aldrich). The Pten-CaP2 and Pten-CaP8 were generated by infecting Pten-P2 or Pten-P8 cell
lines with Cre-retrovirus followed by 2 weeks of puromycin selection. Cells were assayed in triplicate, and the assay was repeated twice.

**Real-time PCR.** Total RNAs from culture cells were extracted with RNeasy Micro kit (Qiagen). RNAs were reverse transcribed into cDNA with SuperScript III First-Strand Synthesis System for qRT-PCR (Invitrogen), and quantitative PCR was done in the IQ thermal cycler (Bio-Rad) using the iQ SYBR Green Supermix (Bio-Rad) and in triplicate. Results were analyzed by the relative quantification method and expressed as relative RNA levels.

**Western analysis.** Protein lysates were prepared from confluent cells by adding radioimmunoprecipitation assay buffer as described (16). Protein lysate (50 μg) was resolved on SDS-PAGE followed by Western blot analysis using anti-PTEN (9502, Cell Signaling Technologies), AR (N-20, Santa Cruz Biotechnology), P-AKT (9271, Cell Signaling Technologies), total AKT (9272, Cell Signaling Technologies), Nck3.1 (sc-15022, Santa Cruz Biotechnology), Cre (MAB3128, Chemicon), p21(c-43, Santa Cruz Biotechnology), p27 (sc-7941, Santa Cruz Biotechnology), E-cadherin (610181, BD Biosciences), and β-actin (5441, Sigma) antibodies, respectively.

**Spectral karyotyping analysis.** Cells were harvested after mitotic arrest with colcemid (0.05 μg/mL) for 2 h. Hypotonization was done with 0.075 mol/L KCl and a 3:1 mixture of methanol and glacial acetic acid was used for fixation. Slides underwent SKY (Applied Spectral Imaging) hybridization, posthybridization, and analyses following ASI's recommended procedures. The probe cocktail contained 20 differentially labeled chromosome-specific painting probes and Cot-1 blocking DNA. Image acquisition was done using a ScanScope (Aperio, Vista, CA) and a customized optical filter (SKY-1, Chroma Technology). Ploidy was defined by the chromosome count for each metaphase and was noted by a specific range. Chromosomal gain and/or loss were determined by the average of the observed copy number ± 25%. Any structural abnormality seen in two or more cells was considered clonal. On average, 15 cells per cell line were analyzed.

**In vitro cell growth assay.** For the Casodex treatment experiment, cells (5 × 10^4 cells per plate) were plated in medium containing 10% FBS with or without 10 μmol/L Casodex for 3 days. To determine cell growth in charcoal-stripped serum (CSS) medium, cells were seeded into six-well plates at 5 × 10^4 cells per well in the maintenance media containing 10% FBS for 16 h. Plates were then cultured in 4% CSS medium for 5 or 6 days. Cell proliferation was determined by trypan blue exclusion counting live cells using trypan blue dye exclusion method every 2 days. Each cell line was assayed in triplicate, and the assay was repeated twice.

**Soft agar colony formation assay.** Cells were plated at a density of 10,000 cells per plate in 0.3% agar on 6-cm tissue culture dishes coated with 0.6% agar in DMEM growth medium. Twenty days after plating, plates were stained with 0.5 mL 0.005% crystal violet. Colonies were counted under a light microscope (×4). Only colonies larger than 0.1 mm diameter were included.

**Viral transduction.** Adenovirus receptor (AR) knockdown was achieved by infecting GTN-CaP2 and GTN-CaP8 cells with pSIREN-RetroQ-DsRed (pSIREN-R, Clontech Laboratories, Inc.) retrovirus expressing AR-specific short hairpin RNA (shRNA).

**In vivo tumor formation study.** Cells (1 × 10^5) were first mixed with Matrigel (BD Biosciences) solution at a ratio of 1:1 and then inoculated s.c. into severe combined immunodeficiency (SCID) mice (≤3 months of age). Tumor formation was monitored for 3 to 8 weeks. Tumor size was determined by caliper measurements, and tumor volume was calculated by the following ratio formula (V = 0.1257 × L × W^2, where L and W are the shorter axis and the long axis, respectively). To examine the role of WT-PTEN in androgen-independent tumor formation, 72 h after viral infection, infected Myc-CaP cells were replated in CSS medium for an additional 2 days, and then cells (2 × 10^6) were injected into flanks of precastrated SCID or intact SCID mice.

**Histology and immunohistochemical analysis.** Histologic and immunohistochemical analyses were done as described (16). Briefly, formalin-fixed and paraffin-embedded (FFPE) sections were stained with H&E or specific antibodies to AR (N-20, Santa Cruz Biotechnology) and Ki67 (VP-RM04, Vector Laboratories) as described (7). For immunofluorescence staining, pretreated sections were first blocked and then incubated with monoclonal antibodies against AK5 (MMS162-P, Covance), SMA (M851, DAKO) at room temperature for 30 min, followed by incubation with Alexa Fluor 594 goat anti-rabbit immunoglobulin G (IgG; H+L; 1:1,000; Molecular Probes). Sections were counterstained with 4,6-diamidino-2-phenylindole (DAPI) in mounting medium (Vector Laboratories) and analyzed by fluorescence microscopy.

**Statistical analysis.** All data were presented as means ± SE. Statistical calculations were done with Microsoft Excel analysis tools. Differences between individual groups were analyzed by paired t test. P values of <0.05 were considered statistically significant.

**Results**

Establishment and characterization of two isogenic prostatic epithelial cell lines from the Pten conditional knockout model. To facilitate our investigation of the molecular mechanisms underlying Pten-controlled prostate tumorigenesis, we isolated primary prostatic cells from an intact Ptenfl/fl;Bmp-4Cre+ mouse using the same protocol as the generation of Myc-CaP line (15). After serial passages and spontaneous immortalization (see Materials and Methods for details), several clonally derived cell lines were established and from which two lines, named Pten-P2 and Pten-P8, were further characterized and studied herein.

Our initial genotyping analysis suggested that Pten-P2 and Pten-P8 were heterozygous for Pten deletion, although the Cre
transgene could be easily detected in both lines (Fig. 1A, lanes 1 and 3). To rule out possible contamination, two additional rounds of subcloning were done, which further confirmed the heterozygous status of these two lines (data not shown). The incomplete deletion of Pten loxp alleles led us to further investigate the Cre transgene expression, which is under the control of a modified rat probasin promoter (18). Western blot analysis showed very low to undetectable Cre protein expression (Fig. 1B, lanes 1 and 3) and quantitative reverse transcription-PCR (Q-RT-PCR) analysis confirmed significant down-regulation of the endogenous probasin gene in both cell lines (Fig. 1C). Our recent finding showed that probasin is positively regulated by PTEN (16) through NKX3.1 (19): in the absence of PTEN, NKX3.1 expression as well as its downstream target genes, including probasin, are significantly down-regulated to undetectable levels in both human and murine prostate cancer tissues. Consistent with our recent finding (16), Western blot analysis showed very low to undetectable Nkx3.1 expression in both PTEN-P2 and PTEN-P8 lines (Fig. 1B). Cre expression, on the other hand, was significantly enhanced when a NKX3.1-expressing vector was transfected into these cells (Supplementary Fig. S1A).

We then infected PTEN-P2 and PTEN-P8 lines with a retrovirus carrying Cre and puromycin-resistant cassette and the resulting isogenic lines, PTEN-CaP2 and PTEN-CaP8 were generated after 2 weeks of drug selection. PCR-based genotyping and Western analysis showed that PTEN-P2 and PTEN-P8 had indeed lost the second Ptenloxp allele and are null for PTEN function, as evident by the loss of PTEN protein expression and increased P-AKT levels (Fig. 1A and B, lanes 2 and 4). Interestingly, deletion of the second allele of Pten led to increased AR expression in the PTEN-CaP2 cells (comparing AR levels in Fig. 1B, lanes 1 and 2, and quantified in Supplementary Fig. S1B), consistent with our previous finding that PTEN serves as a negative regulator for AR expression (16).

To determine the cellular origin of these established cell lines, we did Q-RT-PCR analysis using primers corresponding to phenotypic markers for the major cell types in the prostate epithelium. As shown in Fig. 1C, all lines coexpress both basal (CK14, AR) and luminal cell (CK8/CK18, AR) but not neuroendocrine markers (Fig. 1C). Furthermore, PSCA, a marker that represents an intermediate stage between basal and luminal cells, the transient amplified cell population (20), is also highly expressed in all four cell lines (Fig. 1C). Taken together, these results suggest that the
parental PTEN-P2 and P8 lines were derived from epithelial cells and display similar expression patterns with the transient amplified cells (20).

**Loss of the second allele of Pten does not cause global chromosomal alterations.** Recent findings (21) have shown a novel nuclear function for PTEN in controlling chromosomal integrity. Chromosomal aberrations have previously been linked to the progression of prostate cancer (22). To examine whether there were any chromosome alterations between the isogenic prostate cells, we did karyotyping analyses using a combination of SKY and G-banding tests (Fig. 2). As summarized in Supplementary Table S1, our study revealed several structural and numerical alterations in each pair: PTEN-P2 and PTEN-CaP2 (Supplementary Fig. S2) contained near-tetraploid chromosome number, with 65 to 84 chromosomes in PTEN-P2 and 76 to 80 chromosomes in PTEN-CaP2, respectively; PTEN-P8 and PTEN-CaP8 had near 6N chromosomes with 113 to 125 chromosomes in PTEN-P8 and 115 to 129 chromosomes in PTEN-CaP8. Importantly, loss of the second allele of Pten did not cause further global structural or numerical changes under our in vitro culture conditions, at least within the sensitivities offered by SKY and G-banding analyses. Interestingly, all of the lines analyzed share several common chromosomal alterations that are highlighted in Supplementary Table S1, including del(7)C-F, +10, and a heteromorphous chromosome 8 with a very small centromere, which may either support their common origin or reflect basic genetic alterations required for immortalization of epithelial cells (23). Significantly, loss of the Y chromosome, which is one of the most frequent cytogenic changes observed in human sporadic prostate tumors (22), was observed in PTEN-P8 and PTEN-CaP8.

**PTEN loss leads to increased anchorage-independent growth in vitro and increased tumorigenic potential in vivo.** As a tumor suppressor, PTEN loss is often associated with a gain of transformation potential (24) as PTEN negatively regulates cell cycle progression, cell migration, and cell survival (25). To determine whether Pten loss of heterozygosity leads to enhanced transformation potential, soft agar assay was employed to examine the colony-forming efficiency of Pten null cells. After 20 days in culture, colonies were photographed and counted. PTEN-CaP2 and PTEN-CaP8 cells formed 5- and 2.5-fold more colonies compared with their parental heterozygous cells, respectively (Fig. 3A, left). In addition, the sizes of Pten null colonies were generally larger than those of heterozygous ones (Fig. 3A, right). PTEN-CaP2 and PTEN-CaP8 cells also expressed decreased levels of the G1 cell cycle inhibitor p27, as compared with their isogenic heterozygous pairs (Fig. 3B). Interestingly, complete loss of PTEN also caused decreased E-cadherin expression (Fig. 3B), a molecule critically important for cell-cell adhesion and tumor invasion (26).

Studies from our group and others showed that PTEN dosage plays a critical role in determining both the onset and progression of prostate cancer (6–10). To examine whether the cell lines we generated could mimic the biological differences between Pten heterozygous and homozygous mutants in vivo, we next checked their tumorigenic potentials in immune incompetent SCID mice. Equal number of cells (1 × 10⁶) was injected s.c. into the flank of male SCID mice, and tumor growth was monitored on a daily basis. Both Pten null lines (PTEN-CaP2 and PTEN-CaP8) were tumorigenic with a latency of 3 weeks. However, no tumor formation could be detected when the same number of Pten heterozygous cells (PTEN-P2 and PTEN-P8) were inoculated and followed up to 4 months (Fig. 3C), suggesting that the dosage effect of PTEN in tumorigenesis control can be recapitulated in these isogenic lines. Histologic analysis indicated that all xenograft tumors maintained AR expression and were positive for the luminal epithelial marker CK8 but not for the mesenchymal marker smooth muscle actin (SMA; Fig. 3D). Consistent with our Q-RT-PCR result, no neuroendocrine marker expression could be detected (data not shown).

**Loss of PTEN promotes androgen-independent growth.** Similar to human prostate cancers, Pten null murine prostate cancers do progress to HRPC after castration (7). To understand whether HRPC development requires additional genetic changes under low androgen levels, we tested the likelihood of the
androgen-independent growth and tumor-forming potential of these cell lines that have never been exposed to such a selective pressure.

We first examined the cell growth property in the presence of androgen antagonist Casodex, a potent, nonsteroidal antiandrogen drug that has been shown to have robust inhibitory effects on the growth of human prostate tumor cell lines, including the androgen-dependent cell line LNCaP (27). Consistent with previous reports (27), Casodex efficiently inhibited LNCaP cell growth but had little effect on the PTEN-CaP2 and PTEN-CaP8 lines we generated in this study (Fig. 4A), indicating that the growth properties of these cell lines are not significantly changed with the addition of Casodex. Additionally, both PTEN-CaP2 and PTEN-CaP8 remained proliferative in the CSS medium (Supplementary Fig. S3).

We then examined the tumor formation in vivo in female SCID mice. Remarkably, both PTEN-CaP2 and PTEN-CaP8 could form tumors in female SCID mice with similar frequency and latency as in males (Fig. 4B). Histologic examination showed no detectable difference in tumors formed by each cell line in either female or male SCID mice. Ki67 index further confirmed similar proliferation potentials of xenograft tumors generated in both male and female recipient mice (Fig. 4C; Supplementary Fig. S4).

To further explore the relationship between loss of PTEN and androgen independence, we first compared the PTEN-CaP lines with the Myc-CaP line we generated recently (15). Although established using an identical culture condition, Myc-CaP cells cannot grow in the androgen-ablated environment in vivo (15). Therefore, the androgen-independent nature of PTEN-CaP cells is unlikely due to the in vitro culture procedure. Interestingly, we did not find del(7)C-F, +10 chromosome abnormalities in Myc-CaP (data not shown) as what we have observed in PTEN-CaP2 and PTEN-CaP8 lines. Whether these chromosome abnormalities play a

Figure 3. Loss of Pten increases anchorage-independent growth properties in vitro and promotes tumorigenesis in vivo. A, left, fold differences in number of colony formation in soft agar from Pten null prostate cells (PTEN-CaP2, PTEN-CaP8) relative to their corresponding isogenic pair (PTEN-P2, PTEN-P8); right, a representative picture showing the colony size difference. B, Western blot analysis showed that PTEN-CaP2 and PTEN-CaP8 had decreased p27, and E-cadherin expressions compared with its corresponding heterozygous control line PTEN-P2 and PTEN-P8. C, equal number of PTEN-P2, PTEN-CaP2 and PTEN-P8, PTEN-CaP8 cells were inoculated s.c. into male SCID mice (n > 6), and tumor incidences at 60 days were compared. D, consecutive sections from a PTEN-CaP8 tumor were stained with antibodies against AR, cytokeratin 8, and smooth muscle actin. Bar, 50 μm.
role in the development of androgen independence is an open question and deserves further investigation.

To further examine whether loss of PTEN plays an intrinsic role in androgen independence, we accessed the impact of PTEN loss on the androgen responsiveness of Myc-CaP cells. Significantly, when infected by a lentivirus-carrying PTEN shRNA (17), Myc-CaP/PTEN-shRNA cells, but not cells infected with empty vector (Fig. 5A), became tumorigenic on both precastrated or intact SCID male mice (Fig. 5B). Taken together, these data suggest that PTEN plays a critical role in determining the androgen-independent growth potential of prostatic epithelial cells.

AR is required for PTEN-controlled HRPC. Loss of PTEN and enhanced AR activity represent two common features of human prostate cancer, especially in HRPC (28). Unfortunately, among various prostate cancer cell lines, PC3 is null for both PTEN and AR (13), DU145 expresses PTEN but has AR loss (14), and LNCaP has mutated AR and PTEN loss (12). The Pten null prostatic epithelial cell lines we generated are AR positive without detectable mutations in the AR coding region (data not shown) and, therefore, can be used to address the relationship between PTEN loss and enhanced AR function. To evaluate the functional significance of AR in PTEN-controlled androgen-independent growth, we used AR shRNA to knockdown endogenous AR expression. Several short hairpins were generated corresponding to three different AR coding regions (29), and after initial analysis, two that showed most significant inhibitory effect were chosen for further functional

Figure 4. PTEN-CaP2 and PTEN-CaP8 are resistant to antiandrogen treatment in vitro and are tumorigenic in vivo in both male and female SCID mice. A, PTEN-CaP2 and PTEN-CaP8 are resistant to antiandrogen treatment. A total of 5 × 10^4 cells per well were plated in a six-well plate in triplicate containing 10% FBS DMEM maintenance medium with or without 10 μmol/L Casodex for 3 d. Live cell numbers were counted using trypan blue dye exclusion method. For each cell line, Casodex-treated cell growth is expressed as the percentage of cell numbers in relation to control DMSO-treated cells (100% growth). Columns, mean; bars, SD; *, P < 0.05. B, equal number (2 × 10^5) of infected Myc-CaP (GFP) and Myc-CaP (PTEN-shRNA) were injected s.c. into the flanks of ultra-precstrated SCID (n = 4) or intact SCID mice (n = 4). Tumors were harvested 21 d after inoculation. Top, tumor incidence difference 21 d after inoculation. Bottom, tumor weight differences among these groups. Columns, mean; bars, SD; *, P < 0.05.

Figure 5. Knocking down PTEN in Myc-CaP cell is sufficient to change its androgen dependency. A, Myc-CaP cells were lentivirally infected with PTEN-targeted shRNA (PTEN-shRNA) or control virus containing GFP (GFP). Seventy-two hours after infection, cells were split into CSS medium for an additional 2 d. Lysates were made and analyzed by immunoblot with the indicated antibodies. The remaining cells were used for s.c. injection. B, 2 × 10^5 infected Myc-CaP (GFP) and Myc-CaP (PTEN-shRNA) were injected s.c. into the flanks of either precastrated SCID (n = 4) or intact SCID mice (n = 4). Tumors were harvested 21 d after inoculation. Top, tumor incidence difference 21 d after inoculation. Bottom, tumor weight differences among these groups. Columns, mean; bars, SD; *, P < 0.05.
studies. As shown in Fig. 6A, the endogenous AR expression in PTEN-CaP2 and PTEN-CaP8 cells was reduced to almost undetectable levels upon shRNA-1 treatment, but shRNA-2 had less effect. At the same time, the G1 cell cycle inhibitors p21 and p27 levels were significantly increased (Fig. 6A).

A growing body of evidence suggests that siRNA could generate off-target effects through different mechanisms (30–32). To exclude the potential effects of nonspecific IFN response by siRNA, we assessed the induction of 2’-5’-oligoadenylate synthetase (OSA1), 2’-5’-oligoadenylate synthetase 2 (OAS2), and IFNβ1 (IFNB1), three classic IFN target genes. As shown in Fig. 6B, no significant differences in OSA1, OAS2, as well as IFNB1 mRNA levels were detected when we compared with cells bearing control shRNA and AR shRNA-1 (Fig. 6B), indicating that the effect of AR shRNA was not mediated by general IFNβ response.

To further measure the biological effects of AR knockdown in Pten null cells, we first compared cell growth properties with control shRNA or AR shRNA-1 in androgen-ablated conditions. As shown in Fig. 6C, cell proliferation rates were significantly reduced in both PTEN-CaP2 and PTEN-CaP8 cells infected by AR shRNA-1, suggesting that AR plays an essential role in the cell cycle progression of Pten null prostatic epithelial cells. Importantly, AR knockdown significantly impaired the in vivo tumorigenic potentials of Pten null cells in female SCID mice (Fig. 6D). Taken together, our results indicate that AR is required for PTEN-controlled androgen-independent prostate tumorigenesis.

Discussion

One major obstacle to exploring the mechanisms underlying HRPC progression is the shortage of good model systems, either in vivo or in vitro, that can truly reflect human prostate cancer progression. The Pten murine prostate cancer model provides a valuable resource for studying the mechanism of HRPC (7). Here we report the characterization of two pairs of isogenic prostate cell lines established from the Pten null prostate cancer model. These

![Figure 6](https://www.aacrjournals.org)
murine prostate cancer cell lines not only mimic the biological difference between Pten heterozygous and homozygous mutants in vivo, but also provide the molecular insight into the critical role of PTEN in tumorigenesis and androgen responsiveness. Loss of PTEN enables cells to acquire transforming abilities without a significant change in global chromosome structure. Furthermore, loss of PTEN promotes androgen-independent growth in vitro and in vivo. Knockdown of PTEN expression, on the other hand, is sufficient to convert androgen-dependent Myc-CaP cells to androgen-independent growth, indicating PTEN’s intrinsic role in regulating androgen-dependent growth. Using a shRNA approach, our study further shows the critical role of AR in PTEN-controlled androgen-independent tumorigenesis. Collectively, the murine cell lines established from our study can be used as research tools and may provide a unique opportunity for exploring both the molecular mechanism underlying HRPC and the development of new targeted therapies.

One interesting observation we made was that the two original spontaneously immortalized lines are Pten heterozygous, although the mouse from which the cell lines were generated was clearly Pten<sup>aloxp/aloxp;PBCre4+</sup>. There are several explanations for this result. First, although the majority prostate epithelial cells in Pten<sup>aloxp/aloxp;PBCre4+</sup> mice are PTEN null, minor PTEN-positive stained cells can be detected in these mutant mice (7, 16). This may be due to the relative lower Cre activity in the basal cell compartment as a result of low AR expression (33, 34). Therefore, it is not surprising to see the existence of Pten heterozygous cells in the prostate cancer derived from Pten<sup>aloxp/aloxp;PBCre4+</sup>. Secondly, in vitro spontaneous immortalization methods may preferentially enrich certain types of prostate cells. Primary mouse epithelial cell lines derived from genetically engineered mouse prostate cancer models including TRAMP-C1 (35), Myc-CaP (15), and our established lines here all share similar expression of PSCA, a marker for transient amplified cell population (20). Luminal cells with higher AR and probasin expressions and complete PTEN deletion may be selected out during this long-term establishment procedure. Thirdly, the Cre gene expression was silenced in part due to the feedback loop of PTEN-NKX-AR that can shutdown probasin promoter activity after Pten deletion (ref. 16; see Supplementary Fig. S1A).

HRPC development is a complex process including clonal selection and adaptation (3). It has been postulated that the failure of androgen ablation therapy and development of HRPC might be due to a subpopulation of androgen-independent tumor cells present even before therapy was initiated (36). Indeed, Nks3.1; Pten mutant mice can develop androgen-independent phenotypes well before they display overt PIN or cancer phenotypes (37). Because we can successfully isolate androgen-independent primary cell lines from a primary prostate tumor that has never been exposed to hormonal ablation, our study further supports this hypothesis that acquisition of androgen independence can be uncoupled from hormone deprivation pressure and selection (37).

With recent evidence suggesting that loss of PTEN is associated with progression to HRPC (28, 37, 38), our study further underscores the critical role of PTEN in HRPC development. We showed that complete loss of PTEN causes decreased p27 and E-cadherin expression, which may contribute to the enhanced gain of transformation ability in PTEN-CaP2 and PTEN-CaP8. Significantly, knockdown of PTEN in Myc-CaP cells is sufficient to change its androgen dependency. Collectively, our study showed that PTEN can functionally control “two” hits: cell transformation and androgen-independent growth in the course of HRPC tumor development.

Mounting evidence suggests that AR plays an important role in prostate cancer progression (39–41). Although AR remains critical for cell-cycle progression in androgen-independent CWR22 (42) and LAPC4 (43), the specific role of AR in PTEN-controlled HRPC progression has not been clearly defined yet. Knocking down endogenous AR expression in PTEN-CaP2 and PTEN-CaP8 cells by shRNA abolishes androgen-independent growth in vitro, which in part may be due to the increased expression of cell cycle inhibitor p21 and p27 and less tumorigenicity in vivo in female SCID mice. Therefore, our study provides evidence that HRPC development caused by PTEN loss is androgen independent but AR dependent. Further study will be critical to ascertain whether AR is required for the onset of PIN and whether AR is essential for the acquisition of AI prostate cancer in our Pten prostate cancer model.

Acknowledgments


Grant support: U.S. Army Medical Research and Material Command grants W81XWH-04-1-0824 (J. Jiao) and the Prostate Cancer Foundation, DOD PC031130, National Cancer Institute U01 CA14128-06, P50 CA92131, and RO1 CA107166 (H. Wu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Rachel Kim, Sherly Mosesian, Reggie Hill, and colleagues in both Wu and Sawyers laboratories for helpful comments and suggestion. We acknowledge Prof. Dr. Marieleída Garcia and Margaret Skokan for their great support and advice.

References

Correction: Role of *Pten* in Hormone Refractory Prostate Cancer

In the article on the role of *Pten* in hormone refractory prostate cancer in the July 1, 2007 issue of *Cancer Research* (1), there is an error in Fig. 1A. The corrected figure appears below.


©2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-16-COR2
Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

Jing Jiao, Shunyou Wang, Rong Qiao, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/13/6083

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2007/07/18/67.13.6083.DC1

Cited articles
This article cites 43 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/13/6083.full.html#ref-list-1

Citing articles
This article has been cited by 30 HighWire-hosted articles. Access the articles at:
/content/67/13/6083.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.